Evidence map›Paper›PMID 24905038›Full record

ReviewTranslational research : the journal of laboratory and clinical medicine2015

Epigenomics of Alzheimer's disease.

David A Bennett, Lei Yu, Jingyun Yang, Gyan P Srivastava, Cristin Aubin, Philip L De Jager

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational research : the journal of laboratory and clinical medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Salivary lactoferrin as biomarker for Alzheimer's disease: Brain-immunity interactions.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020
    Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

David A BennettRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Ill. Electronic address: David_A_Bennett@Rush.edu.
Lei YuRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Ill.
Jingyun YangRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Ill.
Gyan P SrivastavaProgram in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass; Program in Medical and Population Genetics, Broad Institute, Cambridge, Mass.
Cristin AubinProgram in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass; Program in Medical and Population Genetics, Broad Institute, Cambridge, Mass.
Philip L De JagerProgram in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass; Program in Medical and Population Genetics, Broad Institute, Cambridge, Mass.

Funding

SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1991 to 2020
$49.1M
EPIDEMIOLOGY OF NEURAL RESERVE AND NEUROBIOLOGY IN AGINGR01AG017917 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2001 to 2023
$43.3M
RISK FACTORS, PATHOLOGY, AND CLINICAL EXPRESSIONS OF ADR01AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1998 to 2024
$21.4M
Pathway discovery, validation and compound identification for Alzheimer's disease - SupplementU01AG046152 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2013 to 2017
$13.6M
Risk Factors, Pathology, and Clinical Expressions of ADRF1AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2014 to 2014
$6.0M
Exploring the Role of the Brain Epigenome: Cognitive Decline and Life ExperiencesRF1AG036042 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2016 to 2016
$5.5M
Exploring the Role of the Brain Epigenome: Cognitive Decline and Life ExperiencesR01AG036042 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2009 to 2013
$4.1M
Exploring the Role of the Brain Transcriptome in Cognitive DeclineR01AG036836 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI DE JAGER, PHILIP L · 2011 to 2014
$2.9M
Cognitive Decline and Dementia: Life Experiences and the Brain Histone EpigenomeRC2AG036547 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2009 to 2010
$998k
NIA NIH HHS P30 AG010161NIA NIH HHS P30AG10161NIA NIH HHS R01 AG015819NIA NIH HHS R01 AG017917NIA NIH HHS R01 AG036042NIA NIH HHS R01 AG036836NIA NIH HHS R01AG15819NIA NIH HHS R01AG17917NIA NIH HHS R01AG36042NIA NIH HHS R01AG36836NIA NIH HHS RC2 AG036547NIA NIH HHS RC2AG36547NIA NIH HHS RF1 AG015819NIA NIH HHS RF1 AG036042NIA NIH HHS U01 AG046152NIA NIH HHS U01AG46152
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a large and growing public health problem. It is characterized by the accumulation of amyloid β peptides and abnormally phosphorylated tau proteins that are associated with cognitive decline and dementia. Much has been learned about the genomics of AD from linkage analyses and, more recently, genome-wide association studies. Several but not all aspects of the genomic landscape are involved in amyloid β metabolism. The moderate concordance of disease among twins suggests other factors, potentially epigenomic factors, are related to AD. We are at the earliest stages of examining the relation of the epigenome to the clinical and pathologic phenotypes that characterize AD. Our literature review suggests that there is some evidence of age-related changes in human brain methylation. Unfortunately, studies of AD have been relatively small with limited coverage of methylation sites and microRNA, let alone other epigenomic marks. We are in the midst of 2 large studies of human brains including coverage of more than 420,000 autosomal cytosine-guanine dinucleotides with the Illumina Infinium HumanMethylation450 BeadArray, and histone acetylation with chromatin immunoprecipitation sequencing. We present descriptive data to help inform other researchers what to expect from these approaches to better design and power their studies. We then discuss future directions to inform on the epigenomic architecture of AD.

Indexed as

Epigenesis, GeneticAlzheimer DiseaseApolipoprotein E4BrainDNA MethylationGenome-Wide Association StudyHistonesHumansMicroRNAsMutationTranslational Research, BiomedicalApolipoprotein E4HistonesMicroRNAs

Identifiers

PMID24905038
PMCPMC4233194

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.